Article Per Year (5 Year)
p-Index From 2021 - 2026
3.002
P-Index
This Author published in this journals
All Journal Medula Manuju : Malahayati Nursing Journal JURNAL PENELITIAN PERAWAT PROFESIONAL Jurnal Keperawatan Profesional (KEPO) JOURNAL OF Qualitative Health Research & Case Studies Reports Journal of Innovative and Creativity Poltekita: Jurnal Pengabdian Masyarakat JPM (Jurnal Pengabdian Masyarakat) Ruwa Jurai
Jausal, Anisa Nuraisa
Unknown Affiliation
Dentistry Education Health Professions Languange, Linguistic, Communication & Media Mathematics Medicine & Pharmacology Neuroscience Nursing Public Health Social Sciences Veterinary Other

Published : 23 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 23 Documents
Search

 1   2   3 
PEMBERDAYAAN KADER MALARIA MELALUI PENYULUHAN DAN PELATIHAN SKRINING MASS BLOOD SURVEY (MBS) DAN RAPID TEST MALARIA DI KECAMATAN TELUK PANDAN WILAYAH KERJA PUSKESMAS HANURA Jausal, Anisa Nuraisa; Suwandi, Jhons Fatriyadi; Kurniawan, Betta; Fadli, Muhammad Yogie; Budyantara, Ronalda
JPM (Jurnal Pengabdian Masyarakat) Ruwa Jurai Vol. 10 No. 2 (2025): JURNAL PENGABDIAN MASYARAKAT RUWA JURAI
Publisher : FK Unila

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.23960/jpmrj.v10i2.3772

Abstract

Kasus malaria di Kabupaten Pesawaran tahun 2023 mencapai 1.915 kasus, dengan Puskesmas Hanura mencatat jumlah tertinggi (1.738 kasus). Kondisi ini menunjukkan perlunya penguatan kapasitas kader malaria dalam deteksi dini dan edukasi masyarakat. Kegiatan pengabdian masyarakat ini bertujuan untuk meningkatkan pengetahuan dan keterampilan kader malaria dalam melakukan skrining menggunakan Mass Blood Survey (MBS) dan Rapid Diagnostic Test (RDT) di Kecamatan Teluk Pandan. Metode kegiatan meliputi penyuluhan, pelatihan teknis, dan evaluasi pre–post test terhadap kader. Sebanyak 30 kader mengikuti kegiatan, menunjukkan peningkatan pengetahuan dari 46,7% menjadi 93,3% (p < 0,05). Sebanyak 85% kader mampu melakukan prosedur RDT dengan benar dan 8 kader baru berhasil direkrut. Program ini berkontribusi terhadap peningkatan kualitas deteksi dini malaria berbasis masyarakat.
Perkembangan Strategi Pengobatan β-Thalassemia Santhi, Komang Ria Yuliana; Sangging, Putu Ristyaning Ayu; Jausal, Anisa Nuraisa; Ismunandar, Helmi
Medula Vol 15 No 4 (2025): Medula
Publisher : CV. Jasa Sukses Abadi

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53089/medula.v15i4.1663

Abstract

β-thalassemia is an inherited blood disorder caused by mutations in the β-globin gene that reduce or eliminate β-globin chain synthesis, leading to hypochromic microcytic anemia and significant morbidity worldwide. The disorder is prevalent in South Asia, Southeast Asia, the Mediterranean, the Middle East, India, and Africa, with approximately 1.5% of the global population identified as carriers. Severe complications, including iron overload, skeletal deformities, heart failure, and multi-organ damage, contribute to its substantial global health burden. This narrative literature review synthesizes evidence from PubMed, Cochrane, and Google Scholar to examine conventional and emerging therapeutic strategies for β-thalassemia, with particular emphasis on recent advances in gene therapy. Standard management relies on regular blood transfusions and iron chelation, which remain supportive and are associated with long-term complications. Hematopoietic stem cell transplantation is the only established curative treatment, especially effective in pediatric patients with matched HLA donors, although its availability is limited. Novel pharmacologic agents, such as luspatercept and mitapivat, have demonstrated reductions in transfusion requirements and improvements in hemoglobin production. Additional approaches, including fetal hemoglobin induction and modulation of iron metabolism, show encouraging potential. A major breakthrough is CRISPR-based gene therapy using exagamglogene autotemcel (Casgevy), approved by the FDA and EMA in 2024, with phase 3 trials reporting transfusion independence in more than 90% of patients and significant quality-of-life improvements. Despite persistent challenges related to cost, access, and long-term safety, these advances indicate a paradigm shift toward precision medicine with curative potential for β-thalassemia.
Overview of treatment success with short, long, and BPaL/M regimens in patients with drug resistant tuberculosis Nasution, Artika Ananda Putri; Soleha, Tri Umiana; Jausal, Anisa Nuraisa; Gozali, Achmad
JOURNAL OF Qualitative Health Research & Case Studies Reports Vol 6 No 1 (2026): January Edition 2026
Publisher : Published by: Indonesian Public Health-Observer Information Forum (IPHORR) Kerjasama dengan Persatuan Perawat Nasional Indonesia (PPNI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.56922/quilt.v6i1.2220

Abstract

Background: Drug-resistant tuberculosis (DR-TB) remains a major challenge in global TB control efforts, particularly in middle-income countries such as Indonesia. Long-term regimens lasting 18–24 months have been associated with low treatment success rates due to their prolonged duration and high incidence of adverse drug reactions. More recent developments, namely the bedaquiline–pretomanid–linezolid regimen with or without moxifloxacin (BPaL/M), have demonstrated treatment success rates of up to 89–90% in international clinical trials. Purpose: To describe the treatment success of short-term, long-term, and BPaL/M regimens among patients with drug-resistant tuberculosis. Method: A retrospective descriptive study was conducted using medical record data of DR-TB patients who received long-term, short-term, or BPaL/M regimens during 2023–2024. Treatment outcome classification followed the WHO 2022 guidelines. The variables collected included patient characteristics, type of regimen, and treatment outcomes based on WHO standards: cured, treatment completed, treatment failed, lost to follow-up, and died. Results: Of the 148 DR-TB patients who met the inclusion criteria, 98 patients (66.2%) received long-term regimens, 17 patients (11.5%) received short-term regimens, and 33 patients (22.3%) were treated with the BPaL/M regimen. The treatment success rate (cured + treatment completed) for the short-term regimen was 76.5%, which was lower compared to the long-term regimen at 83.7%. The BPaL/M regimen demonstrated the highest treatment success rate at 87.9%. Conclusion: The treatment success rates for DR-TB patients at Dr. H. Abdul Moeloek Hospital indicate that the BPaL/M regimen provides the most favorable outcomes compared to long-term and short-term regimens. Keywords: BPaL/M Regimen; Drug-Resistant Tuberculosis; Long-Term Regimen; Short-Term Regimen; Treatment Success.    
Co-Authors Ade Yonata, Ade Adnan, Ayu Zahera Asep Sukohar Azzah Sulya, Hana Azzuhri, Nashwa Amirul Haq Balqis, Gasela Zalianti Betta Kurniawan, Betta Dian Isti Angraini Dinda Parahita, Shabrina Dwiputri, Maliya Finda Eka Putri Rahmadhani Ety Apriliana Fadli, Muhammad Yogie Fala, Arzety Rifda Fayola, Diva Giska Tri Putri Gozali, Achmad Hadibrata, Exsa Hamzah, Muhammad Syafei Hanna Mutiara, Hanna Haq, Rais Amaral Helmi Ismunandar Hendri Busman Ikhsan, Muhammad Al Indri Windarti Intanri Kurniati Irawati, Nur Ayu Virginia Irawati, Nur Bebi Ulfah Iswandi Darwis Jhons Fatriyadi Suwandi Justisia, Adilla Karima, Nisa Mafaazat, Adn Marta, Annisa Tiara Muhammad Maulana Nadifa, Shallu Afdha Nasution, Artika Ananda Putri Novaldi, Faris Novita Carolia Prayogi, Norbertus Marcell Purnomo, Rizki Agung Ramdani, Resti Rangga Firdaus Ratna, Maya Ganda Rekha Nova Iyos, Rekha Nova Reni Zuraida Risyhade, Vania Putri Ronalda Budyantara Sangging, Putu Ristyaning Ayu Santhi, Komang Ria Yuliana Saputra, Wahyu Agung Dwi Setiorini, Anggi Shinta Nareswari, Shinta Sianturi, Maureen Angelica br. Sulya, Hana Susianti Susianti, Susianti TA Larasati Tri Umiana Soleha Utari Gita Mutiara Virginia Irawati, Nur Ayu Wardhana, Fitra Wardhana, Muhammad Fitra Wiwi Febriani Wulan, Anggraini Janar